Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Capsule summary Limited data are available on efficacy and safety of biologics in patients with psoriasis who have metabolic syndrome, Tildrakizumab efficacy was comparable and durable in patients with psoriasis with vs without metabolic syndrome for up to 3 years; safety was consistent with the known profile of tildrakizumab
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research